Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
IMPACT: Influence Modeling for Open-Set Time Series Anomaly Detection
arXiv:2603.29183v1 Announce Type: cross Abstract: Open-set anomaly detection (OSAD) is an emerging paradigm designed to utilize limited labeled data from anomaly classes seen in training to identify both seen and unseen anomalies during testing. Current approaches rely on simple augmentation methods to generate pseudo anomalies that replicate unseen anomalies. Despite being promising in image data, these methods are found to be ineffective in time series data due to the failure to preserve its
-
cs.AI, q-bio.NC updates on arXiv.org
-
UniAI-GraphRAG: Synergizing Ontology-Guided Extraction, Multi-Dimensional Clustering, and Dual-Channel Fusion for Robust Multi-Hop Reasoning
arXiv:2603.25152v2 Announce Type: replace Abstract: Retrieval-Augmented Generation (RAG) systems face significant challenges in complex reasoning, multi-hop queries, and domain-specific QA. While existing GraphRAG frameworks have made progress in structural knowledge organization, they still have limitations in cross-industry adaptability, community report integrity, and retrieval performance. This paper proposes UniAI-GraphRAG, an enhanced framework built upon open-source GraphRAG. The framewo
UniAI-GraphRAG: Synergizing Ontology-Guided Extraction, Multi-Dimensional Clustering, and Dual-Channel Fusion for Robust Multi-Hop Reasoning
-
Oncogene - Issue - nature.com science feeds
-
Correction: The multifunctional RNA helicase DDX39A drives glioblastoma progression by modulating WISP1 alternative splicing that induces an immunosuppressive macrophage polarization
Oncogene, Published online: 01 April 2026; doi:10.1038/s41388-026-03756-2Correction: The multifunctional RNA helicase DDX39A drives glioblastoma progression by modulating WISP1 alternative splicing that induces an immunosuppressive macrophage polarization
Correction: The multifunctional RNA helicase DDX39A drives glioblastoma progression by modulating WISP1 alternative splicing that induces an immunosuppressive macrophage polarization
Oncogene, Published online: 01 April 2026; doi:10.1038/s41388-026-03756-2
Correction: The multifunctional RNA helicase DDX39A drives glioblastoma progression by modulating WISP1 alternative splicing that induces an immunosuppressive macrophage polarization-
Oncogene - Issue - nature.com science feeds
-
STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4
Oncogene, Published online: 01 April 2026; doi:10.1038/s41388-026-03752-6STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4
STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4
Oncogene, Published online: 01 April 2026; doi:10.1038/s41388-026-03752-6
STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4-
Nature - Issue - nature.com science feeds
-
Nanoscale transfer-printed full-colour ultrahigh-resolution quantum dot LEDs
Nature, Published online: 01 April 2026; doi:10.1038/s41586-026-10333-wA dual-action force dynamics strategy using a hard silicon template as a nanoimprinting stamp combined with inverted transfer printing is described for the manufacture of high-performance full-colour ultrahigh-resolution quantum dot light-emitting diodes (LEDs) for active-matrix displays, while revealing electric-field reconstruction in nanoscale arrays and introducing dielectric matching to mitigate field concentration and p
Nanoscale transfer-printed full-colour ultrahigh-resolution quantum dot LEDs
Nature, Published online: 01 April 2026; doi:10.1038/s41586-026-10333-w
A dual-action force dynamics strategy using a hard silicon template as a nanoimprinting stamp combined with inverted transfer printing is described for the manufacture of high-performance full-colour ultrahigh-resolution quantum dot light-emitting diodes (LEDs) for active-matrix displays, while revealing electric-field reconstruction in nanoscale arrays and introducing dielectric matching to mitigate field concentration and performance degradation.-
MRD
-
Circulating Tumor DNA in Cholangiocarcinoma: A Precision Oncology Roadmap
Cancer Manag Res. 2026 Feb 6;18:574678. doi: 10.2147/CMAR.S574678. eCollection 2026.ABSTRACTCholangiocarcinoma (CCA) is a rare but aggressive malignancy with a rising global incidence and few therapeutic options for advanced disease. In recent decades, precision oncology for CCA has advanced rapidly, particularly through the development of targeted therapies for patients with actionable genetic alterations. These therapies have markedly prolonged survival and improved other clinical outcomes amo
Circulating Tumor DNA in Cholangiocarcinoma: A Precision Oncology Roadmap
Cancer Manag Res. 2026 Feb 6;18:574678. doi: 10.2147/CMAR.S574678. eCollection 2026.
ABSTRACT
Cholangiocarcinoma (CCA) is a rare but aggressive malignancy with a rising global incidence and few therapeutic options for advanced disease. In recent decades, precision oncology for CCA has advanced rapidly, particularly through the development of targeted therapies for patients with actionable genetic alterations. These therapies have markedly prolonged survival and improved other clinical outcomes among patients with unresectable, advanced CCA. The implementation of precision oncology largely depends on detecting genetic mutations to guide patient selection and treatment, using tumor tissue biopsies or liquid biopsies, including circulating tumor DNA (ctDNA) from blood or bile. As a minimally invasive biomarker, ctDNA shows great promise for transforming the clinical management of CCA. This review provides a comprehensive overview of the roles of ctDNA in CCA, including early detection, prognostic stratification, minimal residual disease assessment, recurrence monitoring, therapeutic target identification, and treatment response evaluation. A synthesis of existing studies indicates that bile-derived ctDNA shows superior sensitivity compared with blood-based ctDNA in capturing the genetic profiles and heterogeneity of CCA. We also propose an integrative framework that illustrates how ctDNA profiling can inform diagnosis, treatment, and surveillance across the disease continuum. Because research on ctDNA in CCA remains in its infancy, we discuss current challenges and outline future directions for translating these findings into clinical practice. Collectively, the evidence positions ctDNA-particularly bile-derived ctDNA-as a dynamic tool for real-time genomic profiling, sensitive residual disease detection, and therapy monitoring. This integrative framework provides a roadmap for translating these capabilities into clinical practice, with the potential to enable earlier, more personalized interventions and improve outcomes for patients with CCA.
PMID:41883993 | PMC:PMC13012645 | DOI:10.2147/CMAR.S574678